Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood

Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, Loening SA (1998)
CLINICAL CHEMISTRY 44(5): 1060-1062.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ;
Erscheinungsjahr
Zeitschriftentitel
CLINICAL CHEMISTRY
Band
44
Ausgabe
5
Seite(n)
1060-1062
ISSN
PUB-ID

Zitieren

Jung K, Laube C, Lein M, et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 1998;44(5):1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., & Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., and Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY 44, 1060-1062.
Jung, K., et al., 1998. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), p 1060-1062.
K. Jung, et al., “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”, CLINICAL CHEMISTRY, vol. 44, 1998, pp. 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., Loening, S.A.: Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 44, 1060-1062 (1998).
Jung, K, Laube, C, Lein, M, Lichtinghagen, R, Tschesche, Harald, Schnorr, D, and Loening, SA. “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”. CLINICAL CHEMISTRY 44.5 (1998): 1060-1062.

53 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels.
Kusnierova P, Vsiansky F, Pleva L, Plevova P, Safarcik K, Svagera Z., Scand J Clin Lab Invest 75(6), 2015
PMID: 26151887
Reappraisal of quantitative gel zymography for matrix metalloproteinases.
Prescimone T, Tognotti D, Caselli C, Cabiati M, D'Amico A, Del Ry S, Giannessi D., J Clin Lab Anal 28(5), 2014
PMID: 24648291
Heparin administration leads to rapid decrease in plasma matrix metalloproteinase-9.
Lee R, Adlam D, Antoniades C, Digby JE, Kharbanda RK, Choudhury RP, Channon KM., Int J Cardiol 163(2), 2013
PMID: 22805545
Gastric cancer - The role of matrix metalloproteinases in tumor progression.
Lukaszewicz-Zając M, Mroczko B, Szmitkowski M., Clin Chim Acta 412(19-20), 2011
PMID: 21693112
Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.
Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E, Brünner N., Mol Cell Proteomics 7(2), 2008
PMID: 17998244
Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects.
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA, Tanus-Santos JE., Clin Chem Lab Med 46(1), 2008
PMID: 18194081
Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
Rossignol P, Cambillau M, Bissery A, Mouradian D, Benetos A, Michel JB, Plouin PF, Chatellier G, Jacob MP., Clin Exp Pharmacol Physiol 35(4), 2008
PMID: 18307742
Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal.
Colotti C, Angeli V, Del Ry S, Maltinti M, Vittorini S, Giannessi D., Clin Chem Lab Med 45(10), 2007
PMID: 17727309
Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?.
Davis MT, Auger P, Spahr C, Patterson SD., Proteomics - Clinical Applications 1(12), 2007
PMID: C1686
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis.
Gerlach RF, Tanus-Santos JE., Clin Neurol Neurosurg 108(6), 2006
PMID: 16413675
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JN, Davidson NE, Eastern Cooperative Oncology Group., Clin Breast Cancer 6(6), 2006
PMID: 16595036
Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T., Hum Pathol 37(10), 2006
PMID: 16949931
Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.
Rouy D, Ernens I, Jeanty C, Wagner DR., Anal Biochem 338(2), 2005
PMID: 15745750
Preanalytical conditions and circulating matrix metalloproteinases.
Verspaget HW, Kuyvenhoven JP, van Hoek B., Transplantation 79(6), 2005
PMID: 15785393
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D., Intern Med J 35(6), 2005
PMID: 15892761
Circulating matrix metalloproteinase-9 levels as a possible marker of aortic stiffness.
Tanus-Santos JE, Gerlach RF., Arterioscler Thromb Vasc Biol 25(8), 2005
PMID: 16055752
Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.
Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R., Virchows Arch 444(6), 2004
PMID: 15088144
Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma.
Makowski GS, Ramsby ML., Anal Biochem 322(2), 2003
PMID: 14596841
Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R., Clin Chim Acta 316(1-2), 2002
PMID: 11750276
Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood.
Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL., Clin Chim Acta 325(1-2), 2002
PMID: 12367785
Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H., Clin Chem Lab Med 39(5), 2001
PMID: 11434385
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA., Int J Cancer 85(6), 2000
PMID: 10709099
MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.
Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH., Ann N Y Acad Sci 878(), 1999
PMID: 10415726
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
Jung K, Laube C, Lein M, Türk I, Lichtinghagen R, Rudolph B, Schnorr D, Loening SA., Int J Cancer 78(3), 1998
PMID: 9766579

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 9590387
PubMed | Europe PMC

Suchen in

Google Scholar